BIOMAT Database Logo BIOMAT Database Logo

[Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer]. 1994

K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
Department of Urology, Kyoto Prefectural University of Medicine.

M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy was performed on 27 patients with advanced urothelial cancer. The patients included 20 with bladder cancer, 4 with upper urinary tract cancer and 3 with both lesions. Complete response (CR) was observed in 2 (7.4 +/- 9.9%) patients and partial response (PR) in 10 (37.0 +/- 18.2%) patients after the treatment, i.e., the overall objective response rate was 44.4 +/- 18.7%. The rate of relapse or recurrence in the patients with CR and PR was 100% and 90.0%, respectively. The mean duration of the response was 18.5 +/- 13.4 months and 10.7 +/- 10.9 months for CR and PR, respectively. The overall survival rate after one year was 30.2%. Bone marrow suppression was the most serious side effect. The white blood cell count became below 1,000/microliters in 10 patients (36.7%). Among them, 4 patients suffered from sepsis. In conclusion, M-VAC chemotherapy was effective for induction therapy against advanced urothelial cancer, although the effective duration was short. Further maintenance therapy should be established.

UI MeSH Term Description Entries
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
March 1989, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
September 1988, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
September 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Combination chemotherapy of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for advanced uroepithelial cancer].
March 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
August 1988, Hinyokika kiyo. Acta urologica Japonica,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
October 1991, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
July 1992, Journal of the Formosan Medical Association = Taiwan yi zhi,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
[M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
January 1990, Progress in clinical and biological research,
K Mikami, and S Nakagawa, and H Takada, and K Ebisui, and K Sugimoto, and H Watanabe, and M Maegawa, and M Nakao
Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
January 1992, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!